Do analysts prefer PTIX or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings & valuation, PTIX or ABP?

Abpro is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Abpro N/A N/A -$7.23M -$4.23 N/A

Is PTIX or ABP more profitable?

Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Abpro N/A N/A -344.76%

Do analysts recommend PTIX or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PTIX or QLGN?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is PTIX or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Qualigen Therapeutics N/A N/A -202.16%

Do analysts rate PTIX or PPBT?

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,997.90%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Atrinsic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, PTIX or PPBT?

Purple Biotech is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M -$3.45 N/A Purple Biotech N/A N/A -$26.39M -$18.84 N/A

Is PTIX or PPBT more profitable?

Atrinsic's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Purple Biotech N/A -123.63% -98.72%

Do analysts recommend PTIX or ASLN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PTIX or ASLN more profitable?

Atrinsic's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts recommend ELAB or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELAB or PTIX more profitable?

Atrinsic's return on equity of 0.00% beat PMGC's return on equity. Company Net Margins Return on Equity Return on Assets PMGC N/A -117.82% -70.79% Atrinsic N/A N/A -379.72%

Atrinsic (PTIX) Competitors

$0.22 0.00 (0.00%)

As of 07/24/2026

Compare

PTIX vs. ABP, QLGN, PPBT, ASLN, and ELAB

Should you buy Atrinsic stock or one of its competitors? MarketBeat compares Atrinsic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atrinsic include Abpro (ABP), Qualigen Therapeutics (QLGN), Purple Biotech (PPBT), ASLAN Pharmaceuticals (ASLN), and PMGC (ELAB). These companies are all part of the "pharmaceutical products" industry.

How does Atrinsic compare to Abpro?

Atrinsic (NASDAQ:PTIX) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Abpro	N/A	N/A	-344.76%

Abpro is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Atrinsic's average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
Abpro	Neutral

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 13.7% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Abpro beats Atrinsic on 4 of the 7 factors compared between the two stocks.

How does Atrinsic compare to Qualigen Therapeutics?

Atrinsic (NASDAQ:PTIX) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Qualigen Therapeutics	N/A	N/A	-202.16%

Atrinsic has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
Qualigen Therapeutics	Neutral

Summary

Atrinsic beats Qualigen Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Atrinsic compare to Purple Biotech?

Atrinsic (NASDAQ:PTIX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,997.90%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Atrinsic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atrinsic has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Atrinsic's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Purple Biotech	N/A	-123.63%	-98.72%

In the previous week, Purple Biotech had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Purple Biotech and 0 mentions for Atrinsic. Purple Biotech's average media sentiment score of 1.44 beat Atrinsic's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Atrinsic	Neutral
Purple Biotech	Positive

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Purple Biotech is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A

Summary

Purple Biotech beats Atrinsic on 7 of the 13 factors compared between the two stocks.

How does Atrinsic compare to ASLAN Pharmaceuticals?

Atrinsic (NASDAQ:PTIX) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Atrinsic has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Atrinsic has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Atrinsic is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

In the previous week, ASLAN Pharmaceuticals had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for ASLAN Pharmaceuticals and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Atrinsic	Neutral
ASLAN Pharmaceuticals	Neutral

Atrinsic's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Atrinsic beats ASLAN Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Atrinsic compare to PMGC?

PMGC (NASDAQ:ELAB) and Atrinsic (NASDAQ:PTIX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

22.2% of PMGC shares are held by institutional investors. Comparatively, 8.0% of Atrinsic shares are held by institutional investors. 0.0% of PMGC shares are held by company insiders. Comparatively, 8.0% of Atrinsic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PMGC has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Atrinsic has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

Atrinsic has lower revenue, but higher earnings than PMGC. Atrinsic is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$590K	1.77	-$7.75M	-$168.62	N/A
Atrinsic	N/A	N/A	-$5.53M	-$3.45	N/A

In the previous week, PMGC had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for PMGC and 0 mentions for Atrinsic. PMGC's average media sentiment score of 0.43 beat Atrinsic's score of 0.00 indicating that PMGC is being referred to more favorably in the media.

Company	Overall Sentiment
PMGC	Neutral
Atrinsic	Neutral

Atrinsic's return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
Atrinsic	N/A	N/A	-379.72%

Summary

PMGC beats Atrinsic on 6 of the 11 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$390K	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.03	21.29	27.11	23.64
Price / Sales	N/A	170.12	517.09	89.57
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.11	7.88	10.28	6.07
Net Income	-$5.53M	$23.86M	$3.60B	$331.99M
7 Day Performance	-17.17%	-3.82%	-1.27%	-0.63%
1 Month Performance	-40.09%	-2.61%	-0.37%	-2.00%
1 Year Performance	-93.39%	32.79%	18.30%	13.62%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	N/A	$0.22 flat	N/A	-93.3%	$390K	N/A	N/A	2
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
QLGN Qualigen Therapeutics	0.0078 of 5 stars	$0.80 +2.8%	N/A	-74.0%	$1.35M	N/A	N/A	50
PPBT Purple Biotech	3.4213 of 5 stars	$1.39 +4.5%	$30.00 +2,058.3%	-94.5%	$1.24M	N/A	N/A	20	Short Interest Decrease
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. ABP, QLGN, PPBT, ASLN, and ELAB

How does Atrinsic compare to Abpro?

Summary

How does Atrinsic compare to Qualigen Therapeutics?

Summary

How does Atrinsic compare to Purple Biotech?

Summary

How does Atrinsic compare to ASLAN Pharmaceuticals?

Summary

How does Atrinsic compare to PMGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. ABP, QLGN, PPBT, ASLN, and ELAB

How does Atrinsic compare to Abpro?

Is PTIX or ABP more profitable?

Which has preferable earnings & valuation, PTIX or ABP?

Do analysts prefer PTIX or ABP?

Does the media favor PTIX or ABP?

Do institutionals & insiders hold more shares of PTIX or ABP?

Summary

How does Atrinsic compare to Qualigen Therapeutics?

Which has better valuation & earnings, PTIX or QLGN?

Do analysts recommend PTIX or QLGN?

Is PTIX or QLGN more profitable?

Which has more volatility & risk, PTIX or QLGN?

Do institutionals & insiders have more ownership in PTIX or QLGN?

Does the media prefer PTIX or QLGN?

Summary

How does Atrinsic compare to Purple Biotech?

Do analysts rate PTIX or PPBT?

Which has more volatility & risk, PTIX or PPBT?

Is PTIX or PPBT more profitable?

Does the media prefer PTIX or PPBT?

Do insiders and institutionals have more ownership in PTIX or PPBT?

Which has better valuation and earnings, PTIX or PPBT?

Summary

How does Atrinsic compare to ASLAN Pharmaceuticals?

Which has more volatility and risk, PTIX or ASLN?

Which has better earnings and valuation, PTIX or ASLN?

Does the media refer more to PTIX or ASLN?

Is PTIX or ASLN more profitable?

Do insiders and institutionals believe in PTIX or ASLN?

Do analysts recommend PTIX or ASLN?

Summary

How does Atrinsic compare to PMGC?

Do insiders and institutionals have more ownership in ELAB or PTIX?

Do analysts recommend ELAB or PTIX?

Which has more volatility and risk, ELAB or PTIX?

Which has higher earnings and valuation, ELAB or PTIX?

Does the media favor ELAB or PTIX?

Is ELAB or PTIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools